|
| The authors reported an in vitro model of the placental barrier, based on co-culture of trophoblasts and endothelial cells against a collagen extracellular matrix in a microfluidic platform.
[Acta Biomaterialia] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Human-induced pluripotent stem cells were established from three different hematopoietic stem cell sources—peripheral blood, cord blood, and bone marrow aspirates —using episomal reprogramming vectors and differentiated into functionalred blood cells.
[Stem Cell Research & Therapy] |
|
|
|
| Researchers analyzed and compared the platelet count changes of acute-on-chronic liver failure and patients with liver cirrhosis after umbilical cord MSC (UCMSC) therapy. Subsequently, a subgroup analysis based on UCMSC infusion times and patient age was also performed.
[Stem Cells Translational Medicine] |
|
|
|
| HUCPVC were found to modulate lipopolysaccharide (LPS)-induced activation of kynurenine pathway enzymes and metabolites in the brain associated with neurotoxicity.
[Journal of Inflammation] |
|
|
|
| Researchers compared the ncRNA associated with preeclampsia in exosomes and whole serum to observe the exchange of serum exosomes with trophoblast cells. The results showed that placental alkaline phosphatase was enriched in the isolated exosomes.
[Biotechnology and Genetic Engineering Reviews] |
|
|
|
| Scientists investigated whether a bioengineered micro-porous three-dimensional decellularized amniotic membrane scaffold in combination with adipose-derived stem cells could promote healing in ischemic wounds in a diabetic type 1 rat model.
[Tissue and Cell] |
|
|
|
|
| Investigators focus on DNA hydroxymethylation and its epigenetic regulators in human and mouse placental development and function.
[Clinical Epigenetics] |
|
|
|
|
| Cellenkos® Inc. announced that it had dosed the first patient in a Phase I/Ib study evaluating CK0803 for the treatment of amyotrophic lateral sclerosis. CK0803 is a neurotrophic, allogeneic, umbilical cord blood-derived T regulatory cell therapy that preferentially homes towards the central nervous system.
[Cellenkos®, Inc. (PRNewsire)] |
|
|
|
|
| June 3 – 7, 2023
San Diego, California, United States |
|
|
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Institute for Bioengineering of Catalonia – Barcelona, Spain |
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
